CuraTeQ Wins Fourth EU Biosimilar Approval

  Published 7 months ago

CuraTeQ secured EU marketing authorisation for Dazublys, its fourth biosimilar after recent approvals by 2025.

  • Dazublys joins Zefylti and Dyrupeg with EU approval, expanding CuraTeQ’s international biosimilar portfolio in 2025.
  • Previous approvals include Bevqolva (Dec 2024), Zefylti (May 2025), and Dyrupeg (June 2025), highlighting CuraTeQ’s rapid growth.
  • Aurobindo Pharma manufactures APIs, generics, and services, supporting CuraTeQ’s production capabilities worldwide for global markets.

You might like these

Blue Jet Falls 10% After Q1 Miss

Markets Slip as Trump Slaps Tariffs on India

Carraro India-Mamata Machinery Shares Drop Post-Lock-in Expiry

Boosting MSME Credit Access: PHDCCI Plan

Critical Mineral Supply Chain Risks

L&T, ACWA Power Sign Yanbu Renewable MOU

JK Cement Reports Strong Growth in FY25

News that matters the most ⚡